INTRODUCTION: Despite considerable benefits associated with current drug-eluting stents, continued attention to the safety, efficacy, and deliverability of available drug-eluting stent has led to the development of newer stent. METHODS: This study was a single-centre, prospective, non-randomized, first-in-man study which included clinical follow-up data was collected at 1, 8 and 12 months after the procedure. The study included 105 patients with de novo native coronary artery lesions including multi-vessel disease treated with Supralimus-Core® stent. Repeat angiography was performed 8 months post-stent implantation. RESULTS: At quantitative coronary angiography 8-month luminal late loss was 0.39 ± 0.33 mm in-stent and 0.33 ± 0.35 mm in-segment. The incidence of any major adverse cardiac event at 30 days, 8 months and 12 months was 1 (1%), 6 (6%) and 7 (7%) respectively. CONCLUSION: This study demonstrates that the Supralimus-Core® SES is a safe and effective treatment for patients with obstructive coronary artery disease. ClinicalTrials.gov ID: NCT00811616.
INTRODUCTION: Despite considerable benefits associated with current drug-eluting stents, continued attention to the safety, efficacy, and deliverability of available drug-eluting stent has led to the development of newer stent. METHODS: This study was a single-centre, prospective, non-randomized, first-in-man study which included clinical follow-up data was collected at 1, 8 and 12 months after the procedure. The study included 105 patients with de novo native coronary artery lesions including multi-vessel disease treated with Supralimus-Core® stent. Repeat angiography was performed 8 months post-stent implantation. RESULTS: At quantitative coronary angiography 8-month luminal late loss was 0.39 ± 0.33 mm in-stent and 0.33 ± 0.35 mm in-segment. The incidence of any major adverse cardiac event at 30 days, 8 months and 12 months was 1 (1%), 6 (6%) and 7 (7%) respectively. CONCLUSION: This study demonstrates that the Supralimus-Core® SES is a safe and effective treatment for patients with obstructive coronary artery disease. ClinicalTrials.gov ID: NCT00811616.
Authors: A Kastrati; J Mehilli; J Dirschinger; F Dotzer; H Schühlen; F J Neumann; M Fleckenstein; C Pfafferott; M Seyfarth; A Schömig Journal: Circulation Date: 2001-06-12 Impact factor: 29.690
Authors: N Mercado; E Boersma; W Wijns; B J Gersh; C A Morillo; V de Valk; G A van Es; D E Grobbee; P W Serruys Journal: J Am Coll Cardiol Date: 2001-09 Impact factor: 24.094
Authors: Jonathan R Nebeker; Renu Virmani; Charles L Bennett; Jennifer M Hoffman; Matthew H Samore; Jorge Alvarez; Charles J Davidson; June M McKoy; Dennis W Raisch; Brian K Whisenant; Paul R Yarnold; Steven M Belknap; Dennis P West; Jonathan E Gage; Richard E Morse; Gordana Gligoric; Laura Davidson; Marc D Feldman Journal: J Am Coll Cardiol Date: 2005-12-01 Impact factor: 24.094
Authors: Bo Lagerqvist; Stefan K James; Ulf Stenestrand; Johan Lindbäck; Tage Nilsson; Lars Wallentin Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Adnan Kastrati; Julinda Mehilli; Jürgen Pache; Christoph Kaiser; Marco Valgimigli; Henning Kelbaek; Maurizio Menichelli; Manel Sabaté; Maarten J Suttorp; Dietrich Baumgart; Melchior Seyfarth; Matthias E Pfisterer; Albert Schömig Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: Alain J Nordmann; Peter Hengstler; Bernd M Leimenstoll; Thomas Harr; James Young; Heiner C Bucher Journal: Eur Heart J Date: 2004-01 Impact factor: 29.983
Authors: W J van der Giessen; A M Lincoff; R S Schwartz; H M van Beusekom; P W Serruys; D R Holmes; S G Ellis; E J Topol Journal: Circulation Date: 1996-10-01 Impact factor: 29.690
Authors: Ian T Meredith; John Ormiston; Robert Whitbourn; I Patrick Kay; David Muller; Raoul Bonan; Jeffrey J Popma; Donald E Cutlip; Peter Fitzgerald; Ross Prpic; Richard E Kuntz Journal: EuroIntervention Date: 2005-08 Impact factor: 6.534